Core Viewpoint - The release of the ISO international standard for "Broken Wall Ganoderma Spore Powder" marks a significant advancement in the standardization of traditional Chinese medicine (TCM), promoting quality and international development in the industry [1][2][4]. Group 1: Standardization and Innovation - The ISO standard (ISO/TS 25006:2025) for "Broken Wall Ganoderma Spore Powder" will be implemented in July 2025, following previous standards for other TCM products [2]. - The standard establishes key parameters such as raw material sources, a minimum 95% breaking rate, and a multi-index quality control system, enhancing production technology standardization [4]. - Experts emphasize that TCM standardization is a process of deriving scientific rules from clinical practices to form internationally recognized standards [4]. Group 2: Economic Impact - The implementation of ISO standards has led to significant increases in international trade, with related products seeing trade growth of 284.5% and 37.5% for Ganoderma and Dendrobium, respectively [5]. - The standards have been adopted in 31 countries, including major markets like the US, Canada, Australia, and Germany, facilitating trade recognition [5]. Group 3: International Collaboration - Collaborations with international institutions, such as clinical research on TCM's anti-tumor effects and cardiovascular benefits, are enhancing the scientific basis for standardization [6]. - The Zhejiang provincial government plans to strengthen the internationalization of TCM standards, focusing on local medicinal materials and specialty TCM products [6]. Group 4: Future Directions - The establishment of a comprehensive standard system covering the entire industry chain, from cultivation to clinical evaluation, is seen as essential for enhancing the industry's competitiveness [7]. - The company aims to deepen international standard formulation and promote local medicinal materials globally, particularly in countries along the Belt and Road Initiative [9].

Group 1 - Since January 2026, the A-share market has seen a wave of shareholder return activities, with 8 listed companies announcing various ways to reward investors, including physical gifts, discount coupons, and service rights [1] - This trend reflects the maturation of China's capital market, indicating a diversification in how listed companies return value to investors and a shift towards emotional connection and long-term value recognition in investor relations management [1][3] - Companies like Chen Ke Ming Food Co., Ltd. and Zhejiang Shou Xian Gu Pharmaceutical Co., Ltd. have initiated shareholder return activities, offering free products to shareholders based on their holdings [1][2] Group 2 - Other companies such as Quanjude Group, Furui Group, and Panda Dairy also launched shareholder return activities in January, expressing gratitude to shareholders through various means [2] - The strategy of using products or services to reward shareholders enhances their perception of the company's value and fosters trust and long-term investment willingness, while also serving as a platform for brand promotion [2] - Over the past decade, more than 70 listed companies in the A-share market have conducted shareholder return activities, with over 30 companies doing so in 2025 across various sectors including consumer, cultural tourism, healthcare, and technology [2]

Group 1 - Since January 2026, the A-share market has seen a wave of shareholder return activities, with 8 listed companies announcing various ways to reward investors, including physical gifts, discount coupons, and service rights [1][2] - This trend reflects the maturation of the Chinese capital market, indicating a diversification in how listed companies reward investors and a shift towards emotional connection and long-term value recognition in investor relations management [1][3] - Companies like Chen Ke Ming Food Co., Ltd. and Zhejiang Shou Xian Gu Pharmaceutical Co., Ltd. have initiated shareholder return activities, offering free products to shareholders based on their holdings [1][2] Group 2 - Other companies such as Quanjude Group, Furui Group, and Panda Dairy have also launched shareholder return activities in January, expressing gratitude to shareholders through various means [2] - The strategy of using products or services to reward shareholders enhances their perception of the company's value and fosters trust and long-term investment willingness, while also serving as a platform for brand promotion [2][3] - Over the past decade, more than 70 listed companies in the A-share market have conducted shareholder return activities, with over 30 companies doing so in 2025 across various sectors including consumer, cultural tourism, medical, and technology [2]

证券日报网讯1月29日，寿仙谷（603896）在互动平台回答投资者提问时表示，公司已关注到股吧相关 舆情信息。公司始终尊重所有投资者的交流权利，平等对待所有投资者，所有可能对公司股票交易价格 产生较大影响的重大信息，均会严格按照规定，通过法定媒体(如上海证券交易所网站及《上海证券 报》等)及公司官方渠道予以发布。非官方网络信息来源与动机多样，其真实性与客观性敬请投资者谨 慎甄别。 ...

Core Viewpoint - The company emphasizes the integration of artificial intelligence (AI) technology with the entire traditional Chinese medicine (TCM) industry chain, aiming for intelligent upgrades and high-quality development through AI applications in various core processes [1] Group 1: AI Integration in Operations - The company has developed the world's largest Ganoderma lucidum germplasm information database, utilizing digital breeding simulations and automated phenotype data collection for precise breeding, transitioning from experimental to data-driven biological breeding [1] - AI predictive models and image recognition technologies are employed to create smart farms, enabling precise control of the growth environment for medicinal materials and intelligent quality inspection [1] - The company has independently developed a customer service Q&A robot based on customized large models, establishing an AI dynamic knowledge engine to optimize operational processes and reduce labor costs [1] Group 2: Market and Consumer Insights - AI technology is used to analyze multi-channel data, constructing user profiles based on age, physical condition, and consumption preferences, which aids in precise advertising and personalized product recommendations [1] - The company plans to continue deepening the integration of "AI + TCM" innovation, further promoting intelligent upgrades across the entire industry chain [1]

Core Viewpoint - A new company, Hangzhou Shouxian Valley Commercial Development Co., Ltd., has been established with a registered capital of 100 million RMB, focusing on various business management services and real estate leasing [1] Company Summary - Company Name: Hangzhou Shouxian Valley Commercial Development Co., Ltd. [1] - Legal Representative: Li Zhenyu [1] - Registered Capital: 100 million RMB [1] - Company Type: Limited liability company (natural person investment or holding) [1] - Business Address: 9th Floor, Room 9137, Ming Shi Commercial Building, 515 Ming Shi Road, Shangcheng District, Hangzhou, Zhejiang Province [1] - Business Scope: Includes management services for commercial complexes, enterprise management, consulting, non-residential real estate leasing, social and economic consulting services, and information technology consulting services [1] Shareholding Structure - Shareholder 1: Hangzhou Gufu Enterprise Management Co., Ltd. - 70% [1] - Shareholder 2: Zhejiang Shouxian Valley Investment Management Co., Ltd. - 30% [1] Industry Classification - National Standard Industry: Rental and Business Services > Business Services > Comprehensive Management Services [1] - Business Duration: Until January 27, 2026, with no fixed term thereafter [1] - Registration Authority: Market Supervision Administration of Shangcheng District, Hangzhou [1]

Investment Rating - The industry maintains an "Overweight" rating [9] Core Views - The report highlights the performance of the traditional Chinese medicine (TCM) sector, noting a 0.89% increase in the TCM II index, making it the second-best performing sub-sector in the pharmaceutical industry [3] - The report emphasizes the importance of the 2025 performance outlook and the progress of the essential drug catalog adjustments, with many companies showing positive profit growth [6] - The report suggests that the TCM industry may continue to experience structural differentiation, with companies focusing on external markets and innovation to find new growth points [6] Market Performance - The TCM II index closed at 6406.83 points, up 0.89% for the week, while the overall pharmaceutical index fell by 0.39% [3] - The best-performing companies in the TCM sector included *ST Changyao, ST Xiangxue, and Fangsheng Pharmaceutical, while the worst performers included Zhenbaodao and Pianzaihuang [3] Valuation - The TCM sector's PE (ttm) was 27.34X, up 0.23X week-on-week, with a PB (lf) of 2.3X, also showing a slight increase [4] - The PE is at the 28.89% percentile since 2013, while the PB is at the 5.74% percentile [4] Raw Material Market - The TCM raw material index rose by 1.1% due to increased demand for tonic herbs and price hikes in certain materials [5] - The overall market for TCM materials remains volatile, with a notable increase in demand for tonic herbs [5] Investment Suggestions - The report recommends focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [7] - Specific investment targets include companies with strong R&D capabilities, those less affected by centralized procurement, and brands with strong market presence [13]

Group 1 - The core point of the article is that multiple listed companies, including Furi Co., are launching shareholder reward activities to enhance investor relations and provide incentives for holding shares [1][2][4][5] Group 2 - Furi Co. announced a shareholder reward activity where shareholders holding 10000 shares or more as of January 21 can participate [1][3] - Shareholders with 200,000 shares or more will receive gift boxes valued at 5000 yuan, while those with 10,000 to 200,000 shares will receive gift boxes valued at 500 yuan [3] - The activity will take place from January 28 to January 30, and shareholders must apply personally or designate a representative to claim their gifts [3] Group 3 - Other companies like Shouxiangu, Haoxiangni, and Suyanjingshen are also engaging in similar shareholder reward activities, offering exclusive products at discounted prices [2][4][5] - Shouxiangu is providing special purchase options for its products during the Spring Festival, while Haoxiangni is offering exclusive gift boxes at reduced prices for shareholders [4] - Suyanjingshen is celebrating its 10th anniversary by offering free experience gift boxes to shareholders who provide feedback on the company's development [5] Group 4 - Furi Co.'s main business includes home textile and new materials, with a reported revenue of 3.841 billion yuan for the first three quarters of 2025, a decrease of 4.45% year-on-year, and a net profit of 296 million yuan, down 12.05% year-on-year [3]

证券之星消息，1月22日中药板块较上一交易日下跌0.13%，天目药业领跌。当日上证指数报收于 4122.58，上涨0.14%。深证成指报收于14327.05，上涨0.5%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | | 300391 | *ST长药 | 0.77 | 20.31% | | 32.78万 | | 2516.12万 | | 603896 | 寿仙谷 | 22.28 | 3.92% | | 6.29万 | | 1.39亿 | | 002864 | 盘龙药业 | 37.30 | 3.32% | | 8.06万 | | 3.00亿 | | 661509 | ST葫芦娃 | 7.08 | 2.76% | | 4.46万 | | 3125.21万 | | 603139 | 康惠股份 | 22.23 | 2.44% | | 2.62万 | | 5796.86万 | | 600222 | 太龙药业 | 6.68 | 2.14% | | 17 ...

| 证券代码：603896 | 证券简称：寿仙谷 | | 公告编号：2026-002 | | --- | --- | --- | --- | | 债券代码：113660 | 债券简称：寿 22 | 转债 | | 浙江寿仙谷医药股份有限公司 关于 2026 年春节股东回馈活动的公告 活动期间，公司股东及股东代表可以按股东专属优惠价格购入以下产品，每 个产品每人限购 2 份。 | 产品名称 | 原价 | 股东尊享价 | | --- | --- | --- | | 寿仙谷牌破壁灵芝孢子粉片-去壁款 （6 片*10 支/盒）3 盒/份 | 元 5940 | 元 4158 | | 寿仙谷无糖铁皮枫斗颗粒（2g*10 包/盒）3 盒/份 | 元 894 | 元 589 | | 寿仙谷铁皮枫斗灵芝浸膏（130g/瓶）1 瓶/份 | 元 3760 | 元 2629 | 四、活动参与方式 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 值此丙午马年新春佳节来临之际，为切实落实长效、多样的股东回报机制， 感恩广大股东长期以来对浙江寿仙谷医药股份有 ...